ASX - By Stock
|
OCC |
Re:
Veritas 0.90c valuation
|
|
Speckled
|
43 |
21K |
7 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
43
|
21K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Change of Director's Interest Notice - Paul Anderson
|
|
Speckled
|
19 |
5.9K |
5 |
19/06/23 |
19/06/23 |
ASX - By Stock
|
19
|
5.9K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
Media thread
|
|
Speckled
|
553 |
176K |
3 |
06/06/23 |
06/06/23 |
ASX - By Stock
|
553
|
176K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Media thread
|
|
Speckled
|
553 |
176K |
5 |
05/06/23 |
05/06/23 |
ASX - By Stock
|
553
|
176K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
Ann: John Van Der Wielen appointed Independent Non-Exec Chair
|
|
Speckled
|
10 |
3.8K |
10 |
29/05/23 |
29/05/23 |
ASX - By Stock
|
10
|
3.8K
|
10
|
|
ASX - By Stock
|
IHL |
Re:
Why is IHL forum so popular?
|
|
Speckled
|
19 |
8.0K |
8 |
22/05/23 |
22/05/23 |
ASX - By Stock
|
19
|
8.0K
|
8
|
|
ASX - By Stock
|
OCC |
Re:
Small Holders
|
|
Speckled
|
11 |
3.1K |
3 |
18/05/23 |
18/05/23 |
ASX - By Stock
|
11
|
3.1K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
16 |
25/04/23 |
25/04/23 |
ASX - By Stock
|
1.7K
|
498K
|
16
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
10 |
12/04/23 |
12/04/23 |
ASX - By Stock
|
1.7K
|
498K
|
10
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Leading US-based nerve surgeons appointed to advisory board
|
|
Speckled
|
32 |
9.8K |
4 |
29/03/23 |
29/03/23 |
ASX - By Stock
|
32
|
9.8K
|
4
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Ortho-ATI Shoulder Tendon Study Update Revised
|
|
Speckled
|
93 |
23K |
5 |
18/03/23 |
18/03/23 |
ASX - By Stock
|
93
|
23K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
2 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
1.7K
|
498K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
3 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
1.7K
|
498K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
4 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
1.7K
|
498K
|
4
|
|
ASX - By Stock
|
BCI |
Re:
BCI Sweeps
|
|
Speckled
|
8 |
3.9K |
6 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
8
|
3.9K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani
|
|
Speckled
|
47 |
14K |
4 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
47
|
14K
|
4
|
|
ASX - By Stock
|
OCC |
Re:
Perth Treatment
|
|
Speckled
|
6 |
2.0K |
2 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
6
|
2.0K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Perth Treatment
|
|
Speckled
|
6 |
2.0K |
2 |
10/03/23 |
10/03/23 |
ASX - By Stock
|
6
|
2.0K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani
|
|
Speckled
|
47 |
14K |
4 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
47
|
14K
|
4
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani
|
|
Speckled
|
47 |
14K |
2 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
47
|
14K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Orthocell Appoints Non-Executive Director Dr Ravi Thadhani
|
|
Speckled
|
47 |
14K |
5 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
47
|
14K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
6 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
1.7K
|
498K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Half Yearly Report and Accounts
|
|
Speckled
|
14 |
4.8K |
3 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
14
|
4.8K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Half Yearly Report and Accounts
|
|
Speckled
|
14 |
4.8K |
2 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
14
|
4.8K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
3 |
18/02/23 |
18/02/23 |
ASX - By Stock
|
1.7K
|
498K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
5 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
1.7K
|
498K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
4 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
1.7K
|
498K
|
4
|
|
ASX - By Stock
|
IHL |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Speckled
|
16 |
8.6K |
1 |
03/02/23 |
03/02/23 |
ASX - By Stock
|
16
|
8.6K
|
1
|
|
ASX - By Stock
|
OCC |
Re:
Next Significant Milestone
|
|
Speckled
|
36 |
9.9K |
6 |
25/01/23 |
25/01/23 |
ASX - By Stock
|
36
|
9.9K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Next Significant Milestone
|
|
Speckled
|
36 |
9.9K |
4 |
24/01/23 |
24/01/23 |
ASX - By Stock
|
36
|
9.9K
|
4
|
|
ASX - By Stock
|
OCC |
Re:
Next Significant Milestone
|
|
Speckled
|
36 |
9.9K |
3 |
19/01/23 |
19/01/23 |
ASX - By Stock
|
36
|
9.9K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
12 |
12/01/23 |
12/01/23 |
ASX - By Stock
|
1.7K
|
498K
|
12
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
1 |
10/01/23 |
10/01/23 |
ASX - By Stock
|
1.7K
|
498K
|
1
|
|
ASX - By Stock
|
OCC |
Re:
Stem Cell Therapy advancements
|
|
Speckled
|
458 |
153K |
5 |
08/01/23 |
08/01/23 |
ASX - By Stock
|
458
|
153K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
7 |
24/12/22 |
24/12/22 |
ASX - By Stock
|
1.7K
|
498K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
OCC Trading
|
|
Speckled
|
1.7K |
498K |
5 |
20/12/22 |
20/12/22 |
ASX - By Stock
|
1.7K
|
498K
|
5
|
|
ASX - By Stock
|
OCC |
Re:
Stem Cell Therapy advancements
|
|
Speckled
|
458 |
153K |
1 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
458
|
153K
|
1
|
|
ASX - By Stock
|
BCI |
Re:
BCI Beautiful Compounding Investment
|
|
Speckled
|
1.2K |
480K |
6 |
12/12/22 |
12/12/22 |
ASX - By Stock
|
1.2K
|
480K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Movement at the Station
|
|
Speckled
|
71 |
22K |
5 |
03/12/22 |
03/12/22 |
ASX - By Stock
|
71
|
22K
|
5
|
|
ASX - By Stock
|
BOQ |
Re:
Ann: BOQ Starts Search for New Chief Executive Officer
|
|
Speckled
|
40 |
20K |
10 |
28/11/22 |
28/11/22 |
ASX - By Stock
|
40
|
20K
|
10
|
|
ASX - By Stock
|
OCC |
Re:
Bio Horizons is marketing Sriate+ directly on its homepage
|
|
Speckled
|
74 |
28K |
6 |
25/11/22 |
25/11/22 |
ASX - By Stock
|
74
|
28K
|
6
|
|
ASX - By Stock
|
OCC |
Re:
Movement at the Station
|
|
Speckled
|
71 |
22K |
2 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
71
|
22K
|
2
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Investor Presentation
|
|
Speckled
|
45 |
16K |
7 |
10/11/22 |
10/11/22 |
ASX - By Stock
|
45
|
16K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Change of Director's Interest Notice LL
|
|
Speckled
|
20 |
6.0K |
3 |
09/11/22 |
09/11/22 |
ASX - By Stock
|
20
|
6.0K
|
3
|
|
ASX - By Stock
|
OCC |
Re:
Bio Horizons is marketing Sriate+ directly on its homepage
|
|
Speckled
|
74 |
28K |
9 |
07/11/22 |
07/11/22 |
ASX - By Stock
|
74
|
28K
|
9
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Remplir Gains Australian Reimbursement
|
|
Speckled
|
62 |
18K |
7 |
05/11/22 |
05/11/22 |
ASX - By Stock
|
62
|
18K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Remplir Gains Australian Reimbursement
|
|
Speckled
|
62 |
18K |
7 |
01/11/22 |
01/11/22 |
ASX - By Stock
|
62
|
18K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
Ann: Investor Presentation
|
|
Speckled
|
45 |
16K |
7 |
27/10/22 |
27/10/22 |
ASX - By Stock
|
45
|
16K
|
7
|
|
ASX - By Stock
|
OCC |
Re:
Ann: OrthoATI Rotator Cuff Study Success With Cross-Over Patients
|
|
Speckled
|
81 |
29K |
0 |
17/10/22 |
17/10/22 |
ASX - By Stock
|
81
|
29K
|
0
|
|
ASX - By Stock
|
OCC |
Re:
Ann: OrthoATI Rotator Cuff Study Success With Cross-Over Patients
|
|
Speckled
|
81 |
29K |
0 |
14/10/22 |
14/10/22 |
ASX - By Stock
|
81
|
29K
|
0
|
|